Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson’s disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

167

Address:

Acorda Therapeutics, Inc. 420 Saw Mill River Road Ardsley NY 10502 United States

Website:

http://www.acorda.com

Phone:

914-347-4300

Leave a comment

Your email address will not be published. Required fields are marked *